Alnylam Pharmaceuticals
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
Brandicourt stepped down from his role as chief executive officer of Sanofi last year.
Although January was a fairly slow month for PDUFA dates for the U.S. Food and Drug Administration, February has a stronger schedule.
With the 2020 elections looming though, and lawmakers across the country drafting legislation aimed at curbing price increases, some companies are carefully examining the landscape as they approach pricing.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
The trial met its primary efficacy endpoint and all tested secondary endpoints.
The U.S. Food and Drug Administration approved Alnylam Pharmaceuticals’ Givlaari (givosiran) for acute hepatic porphyria.
JOBS
IN THE PRESS